GLP-1 receptor agonists (GLP-1 RAs) are a class of weight-loss medications. They include semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®). Tirzepatide is a dual GLP-1/GIP agonist — meaning it targets two hormone pathways. These are not gimmicks. The clinical trial data is real.
In the STEP 1 trial, semaglutide produced average weight loss of 14.9% of body weight over 68 weeks in adults without diabetes. In the SURMOUNT-1 trial, tirzepatide produced up to 22.5% average weight loss. That is more than any prior weight-loss medication.
That is the accurate, honest version.
What these medications do well.
GLP-1 and GIP agonists work mainly by slowing how fast your stomach empties and by suppressing appetite through brain signals. You eat less because you feel full faster and stay full longer. For many patients, this creates an important window — reduced appetite gives the body a chance to start losing weight, and early success builds motivation.
This window is an opportunity. What you do with your nutrition during this time determines your long-term outcome.
Muscle loss is a real concern — and nutrition is the solution.
In the STEP 1 trial, about 39% of the weight lost was muscle — not fat. That is more muscle loss than you see with diet and exercise alone. Losing muscle slows your metabolism and makes it harder to stay at a healthy weight long-term. The fix: eat enough protein — 1.2 to 1.6 grams per kilogram of body weight — and do resistance exercise. A physician-designed meal plan built around your protein targets is how you protect your muscle while on these medications.
Building the habits that outlast the medication.
The STEP 4 trial showed that when people stopped semaglutide after 20 weeks, they regained about two-thirds of the weight they lost — within just one year. This is not a criticism of the drug. It is a biological fact: when the medication stops, your eating habits have to carry the results.
Starting a structured, evidence-based nutrition plan while on GLP-1 or GIP therapy — not after — is the smart approach. Your reduced appetite during therapy makes it easier to change your eating patterns. Use that window.
Cardiovascular risk factors need nutrition, not just fewer calories.
The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (MACE — heart attacks, strokes, cardiovascular death) by 20% in overweight or obese adults. That is meaningful. But diet quality also independently predicts heart outcomes. The PREDIMED trial showed that a Mediterranean dietary pattern alone reduced major cardiovascular events by 30%. A real-food nutrition plan built around heart health is not redundant with GLP-1 therapy — it works with it.
What this app does.
MyNutriCart does not prescribe, recommend, or sell any GLP-1, GIP, or other weight-loss medication. That decision belongs to you and your physician.
What this app provides is physician-designed, evidence-based meal planning built around your specific health profile — your conditions, medications, labs, allergies, and budget. Whether you are on semaglutide or tirzepatide, considering them, or working toward your goals through nutrition alone, the food still has to be right. The medication manages your appetite. MyNutriCart manages your nutrition.
References: Wilding JPH et al., NEJM 2021 (STEP 1); Jastreboff AM et al., NEJM 2022 (SURMOUNT-1); Rubino DM et al., JAMA 2022 (STEP 4); Lincoff AM et al., NEJM 2023 (SELECT); Estruch R et al., NEJM 2013 (PREDIMED).
